REZOLUTE INC (RZLT) Stock Price, Quote, News and Overview
NASDAQ:RZLT - Nasdaq - US76200L3096 - Common Stock - Currency: USD
RZLT Quote, Performance and Key Statistics
4.86
+0.44 (+9.95%)
The current stock price of RZLT is 4.86 USD. In the past month the price increased by 9.95%. In the past year, price increased by 17.68%.
RZLT Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.57 | 336.94B | ||
| AMGN | AMGEN INC | 14.3 | 159.62B | ||
| GILD | GILEAD SCIENCES INC | 14.41 | 138.71B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 117.37B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.36 | 59.14B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 43.00B | ||
| ARGX | ARGENX SE - ADR | 94.8 | 33.28B | ||
| ONC | BEONE MEDICINES LTD-ADR | 6.23 | 26.43B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.02B | ||
| NTRA | NATERA INC | N/A | 22.06B | ||
| BIIB | BIOGEN INC | 8.42 | 19.52B | ||
| INSM | INSMED INC | N/A | 17.89B |
Related stock screener links
About RZLT
Company Profile
Rezolute, Inc. operates as a biopharmaceutical company, which engages in the development of drug therapies for patients with metabolic and orphan diseases. The company is headquartered in Redwood City, California and currently employs 59 full-time employees. The company went IPO on 2011-12-23. Its lead clinical asset, Ersodetug (formerly RZ358), is a potential treatment for hypoglycemia caused by multiple forms of hyperinsulinism including congenital HI and tumor HI. Ersodetug is an intravenously administered human monoclonal antibody that binds to a unique site (allosteric) on the insulin receptor in insulin target tissues, such as in the liver, fat, and muscle. Congenital is a rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas. RZ402, which is an oral plasma kallikrein inhibitor (PKI) being developed as a potential therapy for the chronic treatment of diabetic macular edema (DME). DME is a vascular complication of diabetes and a leading cause of blindness. RZ402 is designed to block bradykinin production and its resulting effects on vascular leakage and inflammation.
Company Info
REZOLUTE INC
275 Shoreline Drive, Suite 500
Redwood City CALIFORNIA 94065 US
CEO: Nevan Elam
Employees: 55
Phone: 16502064507
REZOLUTE INC / RZLT FAQ
What is the stock price of REZOLUTE INC today?
The current stock price of RZLT is 4.86 USD. The price increased by 9.95% in the last trading session.
What is the ticker symbol for REZOLUTE INC stock?
The exchange symbol of REZOLUTE INC is RZLT and it is listed on the Nasdaq exchange.
On which exchange is RZLT stock listed?
RZLT stock is listed on the Nasdaq exchange.
What is the price forecast or stock price prediction for REZOLUTE INC stock?
16 analysts have analysed RZLT and the average price target is 13.52 USD. This implies a price increase of 178.09% is expected in the next year compared to the current price of 4.86. Check the REZOLUTE INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
What is REZOLUTE INC worth?
REZOLUTE INC (RZLT) has a market capitalization of 415.63M USD. This makes RZLT a Small Cap stock.
How many employees does REZOLUTE INC have?
REZOLUTE INC (RZLT) currently has 55 employees.
What are the support and resistance levels for REZOLUTE INC (RZLT) stock?
REZOLUTE INC (RZLT) has a support level at 4.27 and a resistance level at 4.44. Check the full technical report for a detailed analysis of RZLT support and resistance levels.
Should I buy REZOLUTE INC (RZLT) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of RZLT, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of RZLT, evaluating the profitability, health, valuation and growth aspects
- REZOLUTE INC (RZLT) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- REZOLUTE INC (RZLT) Sales and EPS estimates to see what analysts future expectations are.
- REZOLUTE INC (RZLT) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- REZOLUTE INC (RZLT) Insider and Institutional Ownership to learn about the owners and their transactions.
- REZOLUTE INC (RZLT) Stock Chart to make your own analysis
- REZOLUTE INC (RZLT) Latest news and press-releases to stay up to date.
Does REZOLUTE INC (RZLT) stock pay dividends?
RZLT does not pay a dividend.
When does REZOLUTE INC (RZLT) report earnings?
REZOLUTE INC (RZLT) will report earnings on 2025-09-17, after the market close.
What is the Price/Earnings (PE) ratio of REZOLUTE INC (RZLT)?
REZOLUTE INC (RZLT) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.15).
What is the Short Interest ratio of REZOLUTE INC (RZLT) stock?
The outstanding short interest for REZOLUTE INC (RZLT) is 6.66% of its float. Check the ownership tab for more information on the RZLT short interest.
RZLT Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to RZLT. When comparing the yearly performance of all stocks, RZLT is one of the better performing stocks in the market, outperforming 92.37% of all stocks.
RZLT Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to RZLT. RZLT has a great financial health rating, but its profitability evaluates not so good.
RZLT Financial Highlights
Over the last trailing twelve months RZLT reported a non-GAAP Earnings per Share(EPS) of -1.15. The EPS decreased by -0.88% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -77.08% | ||
| ROE | -88.44% | ||
| Debt/Equity | 0 |
RZLT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to RZLT. The Buy consensus is the average rating of analysts ratings from 16 analysts.